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PGI3 PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA
Brook RA 1 , Talley NJ 2 , Choung RS 3 , Smeeding J 4 , Melkonian AK 5 , Kleinman NL 6 1 The JeSTARx Group, Newfoundland, NJ, USA, 2 Mayo Clinic Jacksonville, FL, Rochester, MN, USA, 3 Mayo Clinic, Rochester, MN, USA, 4 JeSTARx Group, Dallas, TX, USA, 5 HCMS Group, Cheyenne, WY, USA, 6 HCMS Group, Paso Robles, CA, USA OBJECTIVES: The etiology of functional dyspepsia (FD) is debated. However, no published data exist on the associated co-morbid conditions with FD. This study aimed to assess the prevalence, services, and costs related to co-morbid conditions associated with FD. METHODS: Retrospective database analysis on a 4-year study period, from January 1, 2001, through December 31, 2004 using payroll data and adjudicated health insurance medical and prescription claims on more than 300,000 employees. Study comparisons were performed among employees with FD and propensity-scorematched employees without FD (controls). Outcome measures included the prevalence, costs and utilization of health services for various comorbid conditions as defined by the Agency for Healthcare Research and Quality (AHRQ). RESULTS: Employees in cohort FD (N = 1669) and a 50:1 matched control-cohort (N = 83,450) were compared. Employee with FD were more likely to have all major diagnostic categories (MDC) including digestive system, blood and blood forming organs, mental disorders, infections and parasitic disease, etc. except pregnancy and prenatal related disease, compared to matched controls. The top MDC prevalence ratios between the two groups were for digestive systems (6.3:1), blood and blood form organs (2.6:1), mental disorders (2.1:1), and infectious & parasitic disease (2.0:1). More interestingly, 18 of the top 30 most prevalent AHRQ "specific" categories were non-specific with the terms like "other" or "undefined" in the title. Moreover, annual medical costs for the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ's Specific Categories and significantly greater (P ≤ 0.05) in 76 categories (29%). Similarly, the services were greater for 179 (69%) of the 261 Specific Categories and significantly greater (P ≤ 0.05) in 110 categories (42%). CONCLUSIONS: Thisstudy showed excess comorbidity in employees with FD compared to employees without FD, might be a major determinant factors for excess health-care services and health-care costs of functional dyspepsia. 3 Roche Brazil, São Paulo, Brazil OBJECTIVES: Hepatitis C affects approximately 180 million people worldwide. It is one of the main causes of liver disease and is the predominant etiology for liver transplantation. This study performs a systematic review and meta-analysis of published randomized controlled trials comparing efficacy of peginterferon-alpha-2a versus peginterferon-alpha-2b both in association with ribavirin in order to assess which is more effective in the treatment of HCV infection. METHODS: A thorough search in MEDLINE, Lilacs, Cochrane library and Embase databases was conducted in the last quarter of 2009. Manual searches in specialized websites were also carried out. Included studies were those which evaluate treatment efficacy of peginterferon alpha-2a versus peginterferon alpha-2b both plus ribavirin for hepatitis C treatment in naïve patients or nonresponders to other therapies not co-infected with HIV. According to heterogeneity test, a fixed or a random-effect models was adopted for meta-analysis. RESULTS: A total of 570 citations (databases citation without duplicates plus manual searches) were found but only seven met the inclusion criteria Overall, peginterferon-alpha-2a has shown higher sustained virological response (SVR) as compared to peginterferon-alpha-2b: 51.7% versus 42.4% (RR = 1.23, IC 95% 1.10 -1.38, assuming a fixed-effect model). For genotypes 1/4: 42.1% versus 33.3% (RR = 1.11, IC 95% 1.02 -1.20, assuming a fixed-effect model) and for genotypes 2/3: 79.2% versus 73.8% (RR = 1.11, IC 95% 1.01 -1.22, assuming a fixedeffect model). CONCLUSIONS: These findings suggest that peginterferon-alpha-2a is associated with a higher clinical response than peginterferon-alpha-2b indicating that it should be used as the standard-of-care therapy. Our results are in line with another recent published systematic review (Awad, 2009) which concluded that peginterferonalpha-2a has a higher SVR as compared to peginterferon-alpha-2b, with similar safety profile.
PGI4 SYSTEMATIC REVIEW AND META-ANALYSIS OF PUBLISHED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFICACY OF PEGINTERFERON-ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B BOTH PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

PGI5 A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS
University of Arizona, Tucson, AZ, USA, 2 University of Arizona, College of Pharmacy, Tucson, AZ, USA OBJECTIVES: To investigate whether the 5-HT3 receptor antagonists-ondansetron, granisetron, tropisetron, and dolasetron-used for the prevention of post-operative nausea and vomiting (PONV) differ in efficacy. METHODS: A meta-analysis was conducted using published studies. A systematic literature search within Pubmed and the Cochrane Library for randomized, controlled, double-blinded studies measuring efficacy in terms of PONV prophylaxis was conducted. The odds of patients exempted from PONV and post-operative vomiting (POV) within each study arm 24 hours after surgery were the primary indices of drug efficacy. Indirect comparisons using random effect models were conducted. Subgroup analyses excluding controversial studies and controlling amount of dose and administration route were also conducted. RESULTS: A total of 82 studies were identified, representing 15,709 patients. In terms of preventing PONV, the analysis indicated that granisetron was statistically significantly better than ondansetron (odds ratio(OR) = 1.46, 95% confidence interval(CI):1.08-2.00) and dolasetron(OR = 1.56, 95%CI: 1.03-2.34); no other statistically significant relationships comparing either two of the four drugs were found. In terms of preventing POV, the four antiemetic drugs had comparable efficacy: granisetron showed similar efficacy as compared to ondansetron(OR = 1.61, 95%CI: 0.99-2.63), tropisetron(OR = 1.70, 95%CI: 0.95-3.05) and dolasetron(OR = 1.35, 95%CI: 0.78-2.27); ondansetron exhibited comparable efficacy as compared to tropisetron(OR = 1.06, 95%CI: 0.63-1.79) and dolasetron(OR = 0.84, 95%CI = 0.52-1.31); tropisetron and dolasetron were also similar in efficacy(OR = 0.80, 95%CI = 0.44-1.37). Subgroup analyses also found that the four drugs did not differ in efficacy. All 5-HT3 receptor antagonists were statistically significantly better than placebo. CONCLUSIONS: With respect to PONV prophylaxis, granisetron was statistically significantly better than ondansetron and dolasetron; ondansetron, tropisetron, and dolasetron exhibit similar efficacy. With respect to POV prophylaxis, ondansetron, granisetron, tropisetron, and dolasetron appeared to have comparable efficacy.
